109 related articles for article (PubMed ID: 38826230)
1. Granzyme K drives a newly-intentified pathway of complement activation.
Donado CA; Jonsson AH; Theisen E; Zhang F; Nathan A; Rupani KV; Jones D; ; Raychaudhuri S; Dwyer DF; Brenner MB
bioRxiv; 2024 May; ():. PubMed ID: 38826230
[TBL] [Abstract][Full Text] [Related]
2. Activation of complement component C5: comparison of C5 convertases of the lectin pathway and the classical pathway of complement.
Rawal N; Rajagopalan R; Salvi VP
J Biol Chem; 2008 Mar; 283(12):7853-63. PubMed ID: 18204047
[TBL] [Abstract][Full Text] [Related]
3. Formation of high affinity C5 convertase of the classical pathway of complement.
Rawal N; Pangburn MK
J Biol Chem; 2003 Oct; 278(40):38476-83. PubMed ID: 12878586
[TBL] [Abstract][Full Text] [Related]
4. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.
Zwarthoff SA; Berends ETM; Mol S; Ruyken M; Aerts PC; Józsi M; de Haas CJC; Rooijakkers SHM; Gorham RD
Front Immunol; 2018; 9():1691. PubMed ID: 30083158
[TBL] [Abstract][Full Text] [Related]
5. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
[TBL] [Abstract][Full Text] [Related]
6. Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2.
Yaseen S; Demopulos G; Dudler T; Yabuki M; Wood CL; Cummings WJ; Tjoelker LW; Fujita T; Sacks S; Garred P; Andrew P; Sim RB; Lachmann PJ; Wallis R; Lynch N; Schwaeble WJ
FASEB J; 2017 May; 31(5):2210-2219. PubMed ID: 28188176
[TBL] [Abstract][Full Text] [Related]
7. Granzyme K
Jonsson AH; Zhang F; Dunlap G; Gomez-Rivas E; Watts GFM; Faust HJ; Rupani KV; Mears JR; Meednu N; Wang R; Keras G; Coblyn JS; Massarotti EM; Todd DJ; Anolik JH; McDavid A; ; Wei K; Rao DA; Raychaudhuri S; Brenner MB
Sci Transl Med; 2022 Jun; 14(649):eabo0686. PubMed ID: 35704599
[TBL] [Abstract][Full Text] [Related]
8. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway.
Wallis R; Dodds AW; Mitchell DA; Sim RB; Reid KB; Schwaeble WJ
J Biol Chem; 2007 Mar; 282(11):7844-51. PubMed ID: 17204478
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
10. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
[TBL] [Abstract][Full Text] [Related]
11. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
12. Human Granzyme K Is a Feature of Innate T Cells in Blood, Tissues, and Tumors, Responding to Cytokines Rather than TCR Stimulation.
Duquette D; Harmon C; Zaborowski A; Michelet X; O'Farrelly C; Winter D; Koay HF; Lynch L
J Immunol; 2023 Aug; 211(4):633-647. PubMed ID: 37449888
[TBL] [Abstract][Full Text] [Related]
13. Complement receptor is an inhibitor of the complement cascade.
Iida K; Nussenzweig V
J Exp Med; 1981 May; 153(5):1138-50. PubMed ID: 6910481
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
16. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
Kinoshita T; Dodds AW; Law SK; Inoue K
Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
[TBL] [Abstract][Full Text] [Related]
17. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
[TBL] [Abstract][Full Text] [Related]
18. Participation of C3 and its ligands in complement activation.
Volanakis JE
Curr Top Microbiol Immunol; 1990; 153():1-21. PubMed ID: 2404692
[TBL] [Abstract][Full Text] [Related]
19. An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase.
Zarantonello A; Presumey J; Simoni L; Yalcin E; Fox R; Hansen A; Olesen HG; Thiel S; Johnson MB; Stevens B; Laursen NS; Carroll MC; Andersen GR
J Immunol; 2020 Sep; 205(6):1678-1694. PubMed ID: 32769120
[TBL] [Abstract][Full Text] [Related]
20. Structural Basis for the Function of Complement Component C4 within the Classical and Lectin Pathways of Complement.
Mortensen S; Kidmose RT; Petersen SV; Szilágyi Á; Prohászka Z; Andersen GR
J Immunol; 2015 Jun; 194(11):5488-96. PubMed ID: 25911760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
